Beta-blocker and calcium channel blocker toxicityMANAGEMENT

TOXICOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

517 items

☷ Legend

01Approach to the Critical Patient/attcp48

Immediate priorities

›Initial stabilization

›Airway protection triggers

›Refractory shock with declining mental status

›Recurrent seizures

›Breathing targets

›SpO2 94-98%

›End-tidal CO2 trending after intubation

›Circulation priorities

›Two large-bore IV lines

›Arterial line for severe shock

›Decontamination timing

›Activated charcoal window within 1-2 hours

›Extended-release ingestion window up to 4 hours if protected airway

High-risk features

›Immediate escalation triggers

›Bradycardia with hypotension

›SBP < 90 mmHg or MAP < 65 mmHg

›Altered mental status

›Ventricular dysrhythmia

›Wide QRS

›Ventricular tachycardia

›Refractory shock

›Vasopressor requirement escalating within 15-30 minutes

›Lactate rising despite fluids

Key concepts

›Toxidrome recognition

›Beta-blocker predominant pattern

›Bradycardia

›Hypoglycemia risk

›QRS widening with membrane-stabilizing agents

›Calcium channel blocker predominant pattern

›Bradycardia or relative bradycardia

›Hyperglycemia

›Vasodilatory shock with dihydropyridines

›Mixed ingestion pattern

›Profound bradycardic shock

›Early refractory hypotension

Consultation and coordination

›System activation

›Poison center consultation early

›Antidote strategy

›Extracorporeal support planning

›Critical care consultation

›High-dose insulin protocol

›Vasopressor escalation pathway

›Cardiology consultation

›Pacing strategy for refractory bradycardia

›Mechanical circulatory support candidacy

›ECMO center contact if shock persists

›Ongoing vasopressor escalation

›Cardiac arrest or peri-arrest state

02History/hx43

Exposure characterization

›Ingestion details

›Agent and formulation

›Immediate-release

›Extended-release

›Dose estimate

›Tablet count

›Strength per tablet

›Time course

›Time of ingestion

›Co-ingestants timing

›Route

›Oral

›Dermal or ocular exposure

Risk modifiers

›Patient factors

›Cardiac disease history

›Heart failure

›Conduction disease

›Renal impairment

›Increased risk with renally cleared beta-blockers

›Diabetes

›Hypoglycemia masking with beta-blockers

›Pregnancy status

›Gestational age

›Fetal viability considerations

Co-ingestants and intent

›Common co-exposures

›Other antihypertensives

›ACE inhibitor

›ARB

›Digoxin

›Additive bradycardia

›Sedatives

›Benzodiazepines

›Alcohol

›Sodium channel blockers

›Tricyclic antidepressant

›Cocaine

›Self-harm risk context

›Prior overdose history

›Prior ICU admission

›Prior antidote use

›Access to large pill quantities

›Multiple prescriptions

›Recent refills

03Physical Exam/exam34

Hemodynamics and perfusion

›Shock phenotype

›Bradycardic shock

›HR < 50 beats/min

›Cool extremities

›Vasodilatory shock

›Warm extremities early

›Wide pulse pressure

›Cardiogenic shock

›Pulmonary edema

›Elevated jugular venous pressure

›Perfusion markers

›Capillary refill delay

›> 3 seconds

›Mottling

›Mental status

›Agitation

›Somnolence

Cardiac and respiratory findings

›Cardiopulmonary exam

›Heart sounds

›Bradycardia

›New murmur

›Lung exam

›Crackles

›Wheeze from beta-blocker bronchospasm

Neurologic and metabolic clues

›Neuro exam

›Seizure activity

›Propranolol risk

›Hypoperfusion-related seizure

›Pupillary findings

›Normal pupils typical

›Mydriasis suggesting co-ingestant

›Bedside glucose

›Hyperglycemia supporting calcium channel blocker

›Hypoglycemia supporting beta-blocker

04Differential Diagnosis/ddx33

Life-threatening mimics

›Cardiovascular emergencies

›Acute coronary syndrome

›ICD-10 I21

›Troponin rise and ECG ischemia

›Massive pulmonary embolism

›ICD-10 I26

›Right heart strain on POCUS

›Cardiac tamponade

›ICD-10 I31.4

›Pericardial effusion with diastolic collapse

›High-grade AV block from intrinsic disease

›ICD-10 I44.2

›Prior conduction history

Toxicologic differentials

›Other bradycardic poisonings

›Digoxin toxicity

›ICD-10 T46.0X1A

›Hyperkalemia

›Clonidine or imidazoline overdose

›ICD-10 T46.5X1A

›Miosis and CNS depression

›Organophosphate poisoning

›ICD-10 T60.0X1A

›Cholinergic syndrome

Metabolic and infectious causes

›Non-toxic etiologies

›Hypothermia

›ICD-10 T68

›Core temperature low

›Severe hypothyroidism

›ICD-10 E03.9

›Myxedema features

›Sepsis

›ICD-10 A41.9

›Fever or hypothermia with lactate elevation

05Laboratory Tests/lt43

Core labs for severity and targets

›Initial laboratory panel

›Basic metabolic profile

›Potassium for dysrhythmia risk

›Creatinine for drug clearance

›Venous or arterial blood gas

›pH for shock severity

›PaCO2 in mmHg if intubated

›Lactate

›Trend every 1-2 hours in shock

›Target downtrending with therapy

›Serum glucose

›Baseline for high-dose insulin protocol

›Target 6-10 mmol/L during therapy

Toxicology and co-ingestant screening

›Co-exposure assessment

›Acetaminophen level

›Early level at 4 hours or immediately if unknown time

›Repeat if extended-release suspected

›Salicylate level

›Repeat level for rising concentrations

›Metabolic acidosis correlation

›Ethanol level

›Sedation confounder

›Hypoglycemia risk

›Pregnancy test

›All patients with pregnancy potential

›Management and disposition implications

Monitoring labs for antidote toxicity

›High-dose insulin monitoring

›Potassium trend

›Target 3.5-5.0 mmol/L

›Repletion threshold < 3.0 mmol/L

›Glucose trend

›Check every 15-30 minutes during titration

›Check every 30-60 minutes when stable

›Magnesium and phosphate

›Replacement targets to prevent dysrhythmia

›Repletion during prolonged infusion

›Lipid emulsion monitoring

›Triglycerides

›Marked elevation risk

›Pancreatitis risk if severe

›Lipemic serum interference awareness

›Spurious lab values

›Delayed laboratory processing

06Diagnostic Tests/dt34

Scoring Systems

›Risk stratification frameworks

›Poison Severity Score

›Mild symptoms without hypotension or dysrhythmia

›Severe symptoms with shock or life-threatening dysrhythmia

›Shock index

›HR divided by SBP trend

›Limitation in bradycardic shock

›Vasopressor escalation trajectory

›Increasing dose requirement within 30-60 minutes

›Trigger for additional antidotes or extracorporeal support

MRI

›Limited role imaging

›Brain MRI indications

›Persistent focal deficits after stabilization

›Concern for ischemic stroke mimic

›Cardiac MRI rarely indicated acutely

›Not a first-line test in tox shock

›Consider only after stabilization for myocarditis question

›Targeted CT use

›CT head indications

›Persistent coma unexplained after resuscitation

›Seizure with persistent altered mental status

›CT angiography chest indications

›Alternative diagnosis concern for massive pulmonary embolism

›Refractory shock with right heart strain on POCUS

Ultrasound

›Point-of-care ultrasound

›Cardiac views

›Global LV function estimate

›RV dilation assessment

›Volume status

›IVC size and collapsibility interpretation limits

›Lung ultrasound for pulmonary edema

›Procedural guidance

›Central access in shock

›Arterial line placement support

07Disposition/dispo37

Level of care

›ICU admission criteria

›Any vasopressor requirement

›Persistent hypotension after fluid challenge

›Escalating vasopressor dosing

›High-dose insulin infusion

›Continuous monitoring requirement

›Frequent glucose and electrolyte checks

›Dysrhythmia risk

›QRS widening

›AV block

›Step-down or monitored bed criteria

›Asymptomatic ingestion with normal vitals

›Observation duration based on formulation

›Normal ECG throughout observation

›Mild symptoms resolved without antidotes

›Stable glucose without infusion

›No recurrent bradycardia

Transfer and advanced support

›Transfer triggers

›Refractory shock despite first-line antidotes

›Persistent MAP < 65 mmHg

›Worsening lactate

›Need for pacing or mechanical support

›Transvenous pacing requirement

›Impella or ECMO consideration

›Extended-release ingestion with delayed toxicity risk

›Prolonged monitoring requirement

›Whole bowel irrigation consideration

Observation timelines

›Monitoring duration concepts

›Immediate-release beta-blocker

›Minimum 6 hours if asymptomatic and normal ECG

›Longer if sustained-release or symptoms

›Immediate-release calcium channel blocker

›Minimum 6-8 hours if asymptomatic and normal ECG

›Longer for sustained-release and amlodipine

›Sustained-release formulations

›Minimum 24 hours observation consideration

›Delayed hypotension risk

08Treatment/t135

Decontamination and enhanced elimination

›Gastrointestinal decontamination

›Activated charcoal

›Single dose 1 g/kg up to 50 g

›Contraindication unprotected airway

›Whole bowel irrigation

›Polyethylene glycol electrolyte solution 1.5-2.0 L/hour adults

›Pediatrics 25-40 mL/kg/hour

›Endpoint clear rectal effluent

›Sustained-release ingestion indications

›Large sustained-release calcium channel blocker ingestion

›Visible pills on abdominal radiograph

›Extracorporeal elimination considerations

›Hemodialysis usefulness limited for lipophilic agents

›Propranolol low dialyzability

›Verapamil low dialyzability

›Dialyzable beta-blockers

›Atenolol

›Sotalol

First-line hemodynamic support

›Fluids and monitoring

›Crystalloid bolus

›Adults 10-20 mL/kg reassessment

›Pediatrics 10-20 mL/kg reassessment

›Early vasopressor support in cardiogenic pattern

›Avoid excessive fluids in pulmonary edema

›POCUS-guided reassessment

›Vasopressor pathway

›Norepinephrine infusion

›Start 0.05-0.1 microg/kg/min

›Titrate every 2-5 minutes to MAP ≥ 65 mmHg

›Epinephrine infusion

›Start 0.05-0.1 microg/kg/min

›Preferred with prominent bradycardia and low inotropy

›Vasopressin adjunct

›0.03 units/min fixed dose

›Add for catecholamine-refractory vasodilatory shock

Targeted antidotes and escalation

›Calcium therapy for calcium channel blocker toxicity

›Calcium chloride IV

›Central line preferred

›Adults 10% solution 10-20 mL IV over 5-10 minutes

›Pediatrics 20 mg/kg elemental calcium equivalent dosing guidance

›Calcium gluconate IV

›Peripheral line option

›Adults 10% solution 30-60 mL IV over 5-10 minutes

›Pediatrics 60 mg/kg calcium gluconate IV

›Repeat bolus strategy

›Re-dose every 10-20 minutes for persistent hypotension

›Clinical endpoint improved perfusion and BP

›Continuous calcium infusion option

›Calcium gluconate 0.5-1.5 mEq/kg/hour

›Ionized calcium target 1.5-2.0 times upper limit of normal

›Glucagon for beta-blocker toxicity

›Bolus

›Adults 3-5 mg IV over 1-2 minutes

›Repeat bolus 3-5 mg if no response

›Infusion

›Start 1-5 mg/hour after response

›Titrate to hemodynamic effect

›Adverse effects management

›Nausea and vomiting risk

›Aspiration risk with depressed mental status

›High-dose insulin euglycemia therapy for CCB and severe BB toxicity

›Initiation prerequisites

›Baseline glucose and potassium documented

›Dextrose infusion ready

›Insulin bolus

›Regular insulin 1 unit/kg IV

›Consider omitting bolus if hypoglycemia risk high

›Insulin infusion

›Start 1 unit/kg/hour

›Titrate up by 0.5-1 unit/kg/hour every 15-30 minutes

›Maximum commonly 10 unit/kg/hour based on response and resources

›Dextrose support

›D10W infusion initial 0.5 g/kg/hour

›Titrate to glucose 6-10 mmol/L

›D50W bolus 25 g for symptomatic hypoglycemia

›Potassium strategy

›Anticipated intracellular shift

›Replete if < 3.0 mmol/L

›Avoid aggressive repletion if adequate perfusion not restored

›Evidence note

›Expert consensus supports early use for refractory shock in CCB toxicity

›Commonly cited as Class IIa recommendation in toxicology guidance

›Atropine and pacing for bradycardia

›Atropine IV

›Adults 1 mg IV every 3-5 minutes

›Maximum 3 mg

›Transcutaneous pacing

›Bridge for unstable high-grade AV block

›Sedation needs balanced against hypotension

›Transvenous pacing

›Consider if persistent unstable bradycardia

›Limited efficacy if profound myocardial depression

Membrane stabilization and dysrhythmia management

›Sodium bicarbonate for wide QRS from membrane-stabilizing beta-blockers

›Bolus

›1-2 mEq/kg IV

›Repeat until QRS narrows or pH 7.50-7.55

›Infusion

›150 mEq sodium bicarbonate in 1 L D5W

›Titrate to QRS and pH targets

›Ventilation coordination

›Avoid hypercapnia during alkalinization

›ABG monitoring with PaCO2 in mmHg

›Magnesium sulfate for torsades de pointes

›Adults 2 g IV over 10-15 minutes

›Pediatrics 25-50 mg/kg IV

›Seizure control

›Benzodiazepines first line

›Lorazepam 0.1 mg/kg IV

›Diazepam 0.15-0.2 mg/kg IV

›Refractory seizures

›Levetiracetam 60 mg/kg IV up to 4.5 g

›Phenobarbital 20 mg/kg IV

Lipid emulsion and advanced rescue

›Intravenous lipid emulsion for lipophilic agent toxicity

›Indications

›Refractory shock after standard antidotes

›Suspected highly lipophilic beta-blocker ingestion

›Dosing

›20% lipid emulsion 1.5 mL/kg bolus over 1-2 minutes

›Infusion 0.25 mL/kg/min for 30-60 minutes

›Repeat bolus for persistent collapse

›Suggested maximum total 10 mL/kg in first 30 minutes

›Complications

›Fat overload syndrome

›Interference with laboratory assays

›Pancreatitis risk

›Extracorporeal life support

›VA-ECMO for refractory cardiogenic shock

›Persistent shock despite vasopressors and high-dose insulin

›Recurrent cardiac arrest with return of spontaneous circulation

›Mechanical circulatory support options

›Intra-aortic balloon pump limited for profound myocardial depression

›Percutaneous ventricular assist device consideration

›Evidence note

›ECLS supported in toxicologic cardiogenic shock based on observational outcomes

›Often cited as Class IIa recommendation in consensus guidance

09Special Populations/sp30

Pregnancy

›Pregnancy considerations

›Maternal stabilization priority

›Placental perfusion depends on maternal perfusion

›Early vasopressor support when needed

›Medication considerations

›High-dose insulin use acceptable with close glucose monitoring

›Glucagon acceptable for maternal rescue

›Obstetric coordination

›Fetal monitoring when viable gestation

›Delivery planning if maternal arrest or peri-arrest

Geriatric

›Older adult considerations

›Higher baseline conduction disease prevalence

›Early pacing consideration

›Lower reserve for hypotension

›Polypharmacy risk

›Co-ingestion of other nodal blockers

›Interaction with antiarrhythmics

›Renal impairment common

›Prolonged toxicity with renally cleared beta-blockers

›Longer observation duration

Pediatrics

›Pediatric considerations

›Weight-based dosing accuracy

›High-dose insulin dosing by kg

›Calcium dosing by kg

›Early hypoglycemia risk

›Beta-blocker ingestion in toddlers

›Frequent glucose checks

›Unintentional ingestion patterns

›Single tablet significant for certain agents

›Child protective evaluation as appropriate

10Background/b53

Epidemiology

›Exposure patterns

›Common agents

›Metoprolol

›Propranolol

›Verapamil

›Diltiazem

›Amlodipine

›High-risk formulations

›Sustained-release verapamil and diltiazem

›Large amlodipine ingestions with delayed shock

›Morbidity drivers

›Refractory hypotension

›Bradyarrhythmia and arrest

Pathophysiology

›Beta-blocker mechanisms

›Decreased chronotropy

›Sinus bradycardia

›AV block

›Decreased inotropy

›Cardiogenic shock

›Pulmonary edema

›Membrane-stabilizing activity

›QRS widening

›Ventricular dysrhythmia

›CNS penetration

›Seizures with propranolol

›Coma in severe overdose

›Calcium channel blocker mechanisms

›L-type calcium channel blockade

›Reduced contractility

›AV nodal depression

›Vascular smooth muscle relaxation

›Vasodilatory shock with dihydropyridines

›Reflex tachycardia sometimes absent in overdose

›Metabolic effects

›Reduced insulin secretion

›Hyperglycemia and lactic acidosis

Therapeutic Considerations

›Rationale for high-dose insulin

›Inotropy improvement via myocardial carbohydrate utilization

›Enhanced intracellular glucose delivery

›Benefit in CCB-induced myocardial depression

›Rationale for calcium

›Overcoming competitive calcium channel blockade

›Improved contractility and conduction

›Rationale for glucagon

›Increased intracellular cAMP independent of beta-receptors

›Transient improvement in heart rate and contractility

›Guideline style recommendations

›Early poison center involvement supported by toxicology societies

›Expert consensus

›Resource coordination for antidotes and ECMO

›High-dose insulin favored for refractory shock in CCB toxicity

›Consensus Class IIa style recommendation

›Earlier initiation associated with improved response

11Patient Discharge Instructions/pdi16

Copy discharge instructions

›Discharge counseling for mild exposure

›Observation completed with stable vitals and normal ECG

›No dizziness

›No syncope

›Return to ED immediately for red flags

›Fainting or near-fainting

›New chest pain

›Trouble breathing

›Severe weakness or confusion

›Persistent vomiting

›Medication safety

›Keep pills in child-resistant containers

›Store medications locked and out of reach

›Follow-up

›Primary care follow-up within 24-72 hours

›Poison center number provided if available locally

12References/r11

Clinical guidelines and consensus

›Toxicology society guidance

›American College of Medical Toxicology guidance on high-dose insulin therapy

›American Academy of Clinical Toxicology position statements on lipid emulsion therapy

›Resuscitation guidance

›American Heart Association scientific statements on toxicologic cardiac arrest and antidotes

›Advanced cardiac life support bradycardia and pacing algorithms

Evidence-based sources

›Key evidence base

›Observational studies supporting high-dose insulin in calcium channel blocker overdose

›Case series supporting glucagon responsiveness in beta-blocker overdose

›Registry and cohort data supporting VA-ECMO for poison-induced cardiogenic shock

›Toxicology textbooks and poison center protocols for dosing standards

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed June 16, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.